Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.70 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | RBP4 | P02753 | 12/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29721046 | 1.00 | HTR2C (0.70) | HTR2CGAATDP1RBP4HTR2B | |
| SCHEMBL15156609 | 0.98 | HTR2C (0.68) | HTR2CGAATDP1RBP4HTR2B | |
| SCHEMBL29720917 | 0.98 | HTR2C (0.68) | HTR2CGAATDP1RBP4HTR2B | |
| SCHEMBL28247607 | 0.96 | HTR2C (0.70) | HTR2CGAATDP1RBP4HTR2B | |
| SCHEMBL5007618 | 0.91 | HTR2C (0.75) | HTR2CGAATDP1RBP4HTR2B | |
| Cyanide SCHEMBL27792035 | 0.88 | HTR2C (0.70) | HTR2CGAATDP1RBP4HTR2B | |
| SCHEMBL4067584 | 0.84 | HTR2C (0.66) | HTR2CGAATDP1RBP4HTR2B | |
| SCHEMBL613612 | 0.82 | HTR2C (1.00) | HTR2CGAARBP4 | |
| SCHEMBL18939661 | 0.82 | HTR2C (0.64) | HTR2CGAATDP1RBP4HTR2B | |
| SCHEMBL22321310 | 0.82 | HTR2C (0.64) | HTR2CGAATDP1RBP4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4543895-A1 | NOVEL IRON-BASED COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF AS CATALYSTS | Université Paris-Saclay (FR) | 2025-04-30 | — | — | EP | disclosed |
| US-20250074874-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2025-03-06 | — | — | US | disclosed |
| WO-2023247697-A1 | NOVEL IRON-BASED COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF AS CATALYSTS | Universite Paris-Saclay (FR) | 2023-12-28 | — | — | WO | disclosed |
| US-20230257349-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. | 2023-08-17 | — | — | US | disclosed |
| US-11674163-B2 | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof | ARENA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11674163-B2 | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof | ARENA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11674163-B2 | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof | ARENA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-4148045-A1 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3- (TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B] INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | Arena Pharmaceuticals, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-11555015-B2 | Compounds useful in the treatment of autoimmune and inflammatory disorders | ARENA PHARMACEUTICALS, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| EP-3378854-B1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | ARENA PHARM INC (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20120295947-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295947-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295947-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| CN-102164891-A | Substituted 1,2,3, 4-tetrahydrocyclopenta [ b ] indol-3-yl acetic acid derivatives useful for the treatment of autoimmune and inflammatory diseases | ARENA PHARM INC | 2011-08-24 | — | — | CN | disclosed |
| WO-2011094008-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011094008-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | WO | disclosed |
| US-20110130409-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| EP-2326621-A1 | SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010011316-A1 | SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100010219-A1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11555015-B2 | Compounds useful in the treatment of autoimmune and inflammatory disorders | S1PR1, S1PR5, S1PR3 | HTR2C 1782/4885GAA 4102/4885TDP1 2283/4885 |
| US-20120295947-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | S1PR1, S1PR5, S1PR2 | HTR2C 1465/4885GAA 4385/4885TDP1 2001/4885 |
| US-20110130409-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | HTR2C 688/4885GAA 3985/4885TDP1 2753/4885 |
| US-11674163-B2 | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof | S1PR1, S1PR5, S1PR2 | HTR2C 1465/4885GAA 4385/4885TDP1 2001/4885 |
| US-20100010219-A1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | HSD11B1, HSD11B2, HSD17B11 | HTR2C 3041/4885GAA 2732/4885TDP1 941/4885 |
| US-20230257349-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | HTR2C 798/4885GAA 3977/4885TDP1 2727/4885 |
| US-20250074874-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | HTR2C 798/4885GAA 3977/4885TDP1 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.